Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis

Mingjie Shao, Tingting Tian, Xinyan Zhu, Yingzi Ming, Yasuko Iwakiri, Shaojun Ye and Qifa Ye _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:66426-66437. https://doi.org/10.18632/oncotarget.19815

Metrics: PDF 1609 views  |   HTML 2542 views  |   ?  


Mingjie Shao1, Tingting Tian2, Xinyan Zhu3, Yingzi Ming1, Yasuko Iwakiri4, Shaojun Ye5 and Qifa Ye1,5

1Department of Transplant Center, Xiangya 3rd Hospital, Central South University, Changsha, China

2Department of Radiology, Changsha 1st Hospital, Changsha, China

3Digestive Disease, Dongfang Hospital, Tongji University, Shanghai, China

4Department of Internal Medicine, Section of Digestive Diseases, Yale University School of Medicine, New Haven, Connecticut, USA

5Department of Transplant, Zhongnan Hospital, Wuhan University, Wuhan, China

Correspondence to:

Qifa Ye, email: [email protected]

Shaojun Ye, email: [email protected]

Keywords: alemtuzumab, ATG, IL-2RAs, kidney transplantation, network meta-analysis

Received: April 04, 2017     Accepted: July 12, 2017     Published: August 02, 2017


To evaluate the efficacy and safety of antibody induction therapies in kidney transplantation. Systematic literature searches were undertaken using MEDLINE, Embase, and Cochrane Library database from 1980 to 2016. Randomized controlled trials (RCTs) comparing three antibody induction therapies (alemtuzumab, interleukin-2 receptor antibodies and antithymocyte globulin) between each other were identified. Bayesian network meta-analysis was used to combine both the direct and indirect evidence on treatment efficacy and its safety. Antibody induction therapy studies, comprising of 18 RCTs (3444 kidney transplant recipients), were included. Overall, alemtuzumab treatment was superior to the ATG group (OR: 0.49, 95% CI: 0.32 to 0.71) and IL-2RAs group (OR: 0.36, 95% CI: 0.25 to 0.52) for reducing the 1-year acute rejection in kidney transplant recipients. Although alemtuzumab treatment was nearly same with ATG group and IL-2RAs group in improving patient survival and renal function, it can reduce the adverse effects of cytomegalovirus infection more efficiently than ATG group (OR: 0.59, 95% CI: 0.32 to 0.95) and IL-2RAs group (OR: 1.08, 95% CI: 0.61 to 1.73). Alemtuzumab was not associated with increased other adverse effects. Alemtuzumab treatment is safe and effective for kidney transplant recipients. No serious adverse effects were observed in trials or in general populations.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19815